Stereotaxis Niobe® ES System Installed at Texas Children’s Hospital
July 08 2016 - 9:00AM
Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative
technologies for the treatment of cardiac arrhythmias, today
announced that Texas Children’s Hospital in Houston has installed
the Company’s Niobe® ES system, making it the only pediatric
hospital in the country to offer the latest generation remote
magnetic navigation platform for ablation procedures. Texas
Children’s is recognized as one of the top children’s hospitals in
the nation, ranked #2 nationally in cardiology and heart surgery by
U.S. News & World Report.
“We are privileged to provide this cutting-edge treatment for
our patients with arrhythmias in whom cardiac ablations are deemed
necessary,” said Dr. Jeffrey Kim, director of the Arrhythmia and
Pacing Service at Texas Children’s. “With the Niobe system, we can
more quickly and aggressively target and ablate abnormal electrical
impulses in young children and patients with structurally complex
anatomy. This is an important tool in our armamentarium for this
highly specialized procedure and undoubtedly advances our approach
to pediatric cardiac rhythm management.”
Kim is one of four physicians utilizing the Niobe system at the
hospital, primarily for patients with congenital heart disease or
Wolf-Parkinson-White syndrome, a type of supraventricular
tachycardia. The Arrhythmia and Pacing Service at Texas Children’s,
which is one of the highest volume pediatric centers in the country
for invasive electrophysiology studies, first installed Stereotaxis
technology in March 2009. In 2012, the hospital conducted a
comparative study of the magnetic platform versus manual catheter
navigation for ablation of accessory pathways in children,
recording significantly reduced fluoroscopy times in the magnetic
patient group, an essential benefit for vulnerable pediatric
patients.
About StereotaxisStereotaxis is a healthcare
technology and innovation leader in the development of robotic
cardiology instrument navigation systems designed to enhance the
treatment of arrhythmias and coronary disease, as well as
information management solutions for the interventional lab. Over
100 issued patents support the Stereotaxis platform, which helps
physicians around the world provide unsurpassed patient care with
robotic precision and safety, improved lab efficiency and
productivity, and enhanced integration of procedural information.
Stereotaxis' core Epoch® Solution includes the Niobe® magnetic
navigation system, the Odyssey® portfolio of lab optimization,
networking and patient information management solutions, and the
Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received
regulatory clearance in the United States, European Union, Canada,
China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator,
V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter
advancement system have received clearance in the United States,
Canada, and the European Union. For more information, please visit
www.stereotaxis.com.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words
"believe”, "estimate”, "project”, "expect" or similar expressions.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's ability to raise additional capital on a timely basis and
on terms that are acceptable, its continued listing on the NASDAQ
Capital Market, its ability to continue to manage expenses and cash
burn rate at sustainable levels, its ability to continue to work
with lenders to extend, repay or refinance indebtedness on
acceptable terms, continued acceptance of the Company's products in
the marketplace, the effect of global economic conditions on the
ability and willingness of customers to purchase its systems and
the timing of such purchases, competitive factors, changes
resulting from the recently enacted healthcare reform in the United
States, including changes in government reimbursement procedures,
dependence upon third-party vendors, timing of regulatory
approvals, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments in any particular period or at all because some
of these purchase orders and other commitments are subject to
contingencies that are outside of the Company's control. In
addition, these orders and commitments may be revised, modified,
delayed or canceled, either by their express terms, as a result of
negotiations, or by overall project changes or delays.
Company Contact:
Martin C. Stammer
Chief Financial Officer
314-678-6155
Investor Contact:
Todd Kehrli / Jim Byers
MKR Group, Inc.
323-468-2300
stxs@mkr-group.com